MTHFR C677T mutation, factor II G20210A mutation and factor V Leiden as risks factor for youth retinal vein occlusion

Filippo Cruciani, A. Moramarco, T. Curto, A. Labate, V. Recupero, L. Conti, G. M. Gandolfo, C. Balacco Gabrieli

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: To determine whether methylene tetrahydrofolate reductase (MTHFR) C677T mutation, factor II G20210A mutation and factor V Leiden are risk factors for retinal vein occlusion (RVO) in patients under fifty years of age. Methods: Comparison of 29 patients, under 50 years old of age, as affected RVO and 62 age matched normal controls. Plasma MTHFR C677T genotype, Factor II G20210A genotype, Factor V Leiden genotype, S protein level, C protein level, APCR presence (Actived Protein C Resistance), homocysteine level and Beta-thromboglobulin level were determined. Results: Seventeen RVO patients and twenty-one controls were heterozygous for the MTHFR C677T mutation. Three RVO patients and twenty-three controls were homozygous for the MTHFR C677T mutation. Three RVO patients and two controls were heterozygous for the factor II G20210A mutation. One control was heterozygous for the factor V Leiden. Conclusions: This study fails to demonstrate that these mutations are risk factors for RVO in patients under fifty years of age.

Original languageEnglish
Pages (from-to)299-303
Number of pages5
JournalClinica Terapeutica
Volume154
Issue number5
Publication statusPublished - Sep 2003

Keywords

  • Factor II G20210
  • Factor V Leiden
  • MTHFR C677T
  • Retinal vein occlusion

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'MTHFR C677T mutation, factor II G20210A mutation and factor V Leiden as risks factor for youth retinal vein occlusion'. Together they form a unique fingerprint.

Cite this